Symphogen and Japan's Meiji Seika Kaisha enter collaboration  

2006.12.12
Symphogen and Meiji Seika Kaisha have entered a collaboration to use Symphogen's technology platform to develop, produce and market recombinant polyclonal antibodies
Danish Biotech company Symphogen and the Japanese pharmaceutical company Meiji Seika Kaisha have entered a collaboration to use Symphogen's technology platform to develop, produce and market recombinant polyclonal antibodies against an undisclosed group of bacteria. Kirsten Drejer, managing director of Symphogen, says Symphogen met research scientists from Meiji for the first time at a Life Science Seminar held by Copenhagen Capacity and Invest in Denmark in 2004.
 
"Meiji is a significant player on the Japanese market in the development of drugs for the treatment of infectious diseases, and we are very pleased that they have chosen Symphogen as a collaboration partner. We see it as a seal of approval of Symhogen's technology platform", comments Drejer.
 
Meiji will initially pay a one-off sum to Symphogen to gain access to its technology platform, as well as subsequent milestone payments and royalties from countries where Meiji markets the product
 
Symphogen pioneers therapeutic products based on recombinant natural human antibodies for the treatment and prevention of human disease. Symphobodies offer a number of advantages over current plasma-derived immunoglobulins and monoclonal antibody therapies for the treatment of infectious diseases, allergy, transplant rejection, and cancer. The commercial potential of symphobodies is expected to be very significant.
 
Link > Symphogen  

Next step

Explore business cases

Please contact me

Name
Company
E-mail
Phone
How can we help you?

IDK
We use cookies to make the website perform optimally. You accept cookies by closing the box or continuing to use the website. Click here to read more about cookies. ×